EVAX Evaxion Biotech
- 3.910
- -0.260-6.24%
- 4.060
- +0.150+3.84%
Evaxion Biotech News
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly lower Wednesday morning, declining 0.36% to 1,359.56 on the S&P Europe Select ADR Index. From continental Euro
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.5% to 1,380.32 on the S&P Europe Select ADR Index. With the gain, the index is set to c
Evaxion Biotech's Strategic Financial Plans
Evaxion Biotech Advances Personalized Cancer Vaccine
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine EVX-01
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3 20
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were weaker Thursday morning, falling 0.91% to 1,353.49 on the S&P Europe Select ADR Index.
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending moderately lower Tuesday morning, declining 0.49% to 1,372.87 on the S&P Europe Select ADR Index. From continental Euro
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European equities traded in the US as American depositary receipts opened the week in positive territory Monday morning, rising 0.50% to 1,380.48 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.27% to 1,369.92 on the S&P Europe Select ADR Index. However, the gain isn't en
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.52% to 1,375.67 on the S&P Europe Select ADR Index. From continental Europe, th
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech with a Buy and maintains $14 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
Earnings Call Summary | Evaxion Biotech(EVAX.US) Q4 2023 Earnings Conference
The following is a summary of the Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript:Financial Performance:Evaxion Biotech reported a net loss of $22.1 million in 2023, a slight reduction com
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Health care stocks were retreating Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding 1.9%. The iShares Biotechnology ETF (IBB) fell 2.2
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies
Evaxion Biotech (EVAX) said Tuesday that three studies showed antigens from its preclinical EVX-B1 vaccine candidate significantly protected large, non-rodent animals against surgical site infections caused by Staphylococcus aureus.
Evaxion Biotech Raised to Buy From Neutral by Ladenburg Thalmann
Evaxion Biotech Raised to Buy From Neutral by Ladenburg Thalmann
Ladenburg Thalmann Upgrades Evaxion Biotech to Buy, Announces $8 Price Target
Ladenburg Thalmann analyst Ahu Demir upgrades Evaxion Biotech (NASDAQ:EVAX) from Neutral to Buy and announces $8 price target.
Evaxion Biotech Concludes Large Non-rodent Animal Infection Studies, Testing Antigens From Evaxion's Preclinical EVX-b1 Vaccine Candidate Against Staphylococcus Aureus, Studies Showed EVX-b1 Antigens Significantly Reduced Disease Burden
Evaxion Biotech Concludes Large Non-rodent Animal Infection Studies, Testing Antigens From Evaxion's Preclinical EVX-b1 Vaccine Candidate Against Staphylococcus Aureus, Studies Showed EVX-b1 Antigens
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion's preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus). In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
Analysis
Price Target
No Data
